Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) has earned an average recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $21.75.

A number of analysts recently commented on UNCY shares. Weiss Ratings upgraded shares of Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 9th. Benchmark reduced their target price on Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating on the stock in a report on Wednesday, July 1st. B. Riley Financial reissued a “buy” rating and issued a $22.00 target price on shares of Unicycive Therapeutics in a research note on Tuesday, June 30th. Wall Street Zen cut Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. Finally, Guggenheim restated a “buy” rating and issued a $37.00 price target (down from $40.00) on shares of Unicycive Therapeutics in a report on Wednesday, May 13th.

Institutional Trading of Unicycive Therapeutics

Hedge funds have recently bought and sold shares of the stock. Vivo Capital LLC lifted its stake in Unicycive Therapeutics by 57.4% in the third quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock valued at $7,804,000 after buying an additional 652,901 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Unicycive Therapeutics in the fourth quarter valued at approximately $5,856,000. Vanguard Group Inc. increased its position in shares of Unicycive Therapeutics by 8.7% during the third quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock worth $2,873,000 after acquiring an additional 52,925 shares in the last quarter. Cantor Fitzgerald L. P. bought a new stake in shares of Unicycive Therapeutics during the fourth quarter worth $1,154,000. Finally, Geode Capital Management LLC increased its position in shares of Unicycive Therapeutics by 36.2% during the fourth quarter. Geode Capital Management LLC now owns 171,290 shares of the company’s stock worth $989,000 after acquiring an additional 45,563 shares in the last quarter. 40.42% of the stock is currently owned by institutional investors and hedge funds.

Unicycive Therapeutics Stock Performance

Shares of NASDAQ UNCY opened at $5.38 on Friday. Unicycive Therapeutics has a 52-week low of $3.71 and a 52-week high of $8.74. The stock has a market cap of $147.36 million, a P/E ratio of -2.43 and a beta of 1.79. The firm has a 50 day moving average price of $6.92 and a 200 day moving average price of $6.77.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its earnings results on Tuesday, May 12th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.08). Analysts predict that Unicycive Therapeutics will post -1.49 earnings per share for the current fiscal year.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.